Organ transplants in HIV infected patients. Update and recommendations;Trasplante de organos en pacientes con infeccion por el virus de la inmunodeficiencia humana. actualizacion y recomendaciones

Medicina

Volumn 71, Issue 1, 2011, Pages 59-65

  Barcan, Laura ^a   Gadano, Adrian ^a   Cassetti, Isabel ^b   Villamil, Federico ^c  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^b Hospital Italiano de Buenos Aires ^*  (Argentina)

^c FUNDIEH   (Argentina)

Author keywords

HIV; Organ transplants

Indexed keywords

ANTIRETROVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT; PROTEINASE INHIBITOR;

ARTICLE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; ORGAN TRANSPLANTATION; SURVIVAL; TREATMENT CONTRAINDICATION; ARGENTINA; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DRUG CONTRAINDICATION; PRACTICE GUIDELINE;

ARGENTINA; HIV INFECTIONS; HUMANS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION;

EID: 79959280598     PISSN: 00257680     EISSN: 16699106     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Rubin RH, Tolkoff-Rubin NE. The problem of human immunodeficiency virus (HIV) infection and transplantation. Transplant Int 1988; 1: 36-42.
2. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatients Study Investigators. N Engl J Med 1998; 338: 853-60.
3. Detels R, Tarwater P, Phair JP, Margolicck J, Riddler SA, Muñoz A. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS 2001;15: 347-55.
4. Soriano V, Miró JM, García-Samaniego J, et al. Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. J Viral Hepat 2004; 11: 2-17.
5. Roland M and Stock P. Liver transplantation in HIV-infected recipients. Semin Liver Dis 2006; 26: 273-284.
6. Ragni M, Belle S, Im K, et al. Survival of Human Immunodeficiency Virus-infected liver transplant recipients. J Infect Dis 2003; 188: 1412-20.
7. Castells L, Escartín A, Bilbao I, et al. Liver transplantation in HIV-HCV coinfected patients: A case-control Study. Transplantation 2007; 83: 354-8.
8. Hirose K, Stock P. Liver transplantation in the human immunodeficiency virus-positive patients. Curr Opin Organ Transplant 2006; 11: 241-6.
9. Miró J, Agüero F, Laguno M, et al. Liver transplantation in HIV/ hepatitis co-infection. Journal of HIV Therapy 2007;12: 24-35.
10. Kumar M, Sierka D, Damask AM, et al. Safety and success of kidney transplantation and concomitant immunosupression in HIV-positive patients. Kidney Int 2005; 67: 1622-9.
11. Qiu J, Terasaki P, Waki K, Cai J, Gjertson D. HIV-Positive renal recipients can achieve survival rates similar to those of HIV-negative patients. Transplantation 2006; 81: 1658-61.
12. Abbott K, Swanson S, Agodoa L, Kimmel P. Human Immunodeficiency Virus infection and kidney transplantation in the era of Highly Active Antirretroviral Therapy and modern immunosupression. J Am Soc Nephrol 2004; 15: 1633-9
13. Trullas J, Miró J, Barril G, Ros S, Burgos F, Moreno A. Trasplante renal en pacientes infectados por el VIH. Enferm Infecc Microbiol Clin 2005; 23: 363-74.
14. Roland M, Barin B, Carlson L, et al. HIV-infected liver and kidney transplant recipients: 1 and 3 year outcomes. Am J Transplant 2008; 8: 355-65.
15. Steinman T, Becker BN, Frost AE, et al. Guidelines for the referral and management of patients eligible for solid organ transplantation. Transplantation 2001; 71: 1189-204.
16. a ed. Texto revisado. Barcelona: Masson; 2002, p 218-25.
17. Neuberger J. Transplantation for alcoholic liver disease. J Hepatol 2002; 36: 1307.
18. Lerdergerber B, Mocroft A, Reiss P, et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. N Engl J Med 2001; 344: 168-74.
19. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119-29.
20. The Antiretroviral Therapy Cohort (ART) Collaboration. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003; 362: 679-86.
21. Miro JM, Laguno M, Moreno A, Rimola A. Hospital Clinic OLT In HIV Working Group. Management of end stage liver disease (ESLD): what is the current role of orthotopic liver transplantation (OLT)? J Hepatol 2006; 44(1 Suppl): S140-5.
22. Pineda JA, Romero-Gómez M, Díaz-García F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 2005; 41: 779-89.
23. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-72.
24. Ragni MV, Eghtesad B, Schlesinger KW, Dvorchik I, Fung JJ, Ragni MV. Pre-transplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transplantation 2005; 11: 1425-1430.
25. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003; 37: 113-28.
26. Gatell JM, Blanco JL, Alcamí J, et al. Documento de consenso de GESIDA sobre la utilización de los estudios de resistencias en la práctica clínica. Enferm Infecc Microbiol Clin 2001; 19: 53-60.
27. Lynch E., White M. Surgical blood exposures after the OSHA bloodborne pathogens standard: frequency and prevention. Todays OR Nurse 1993; 15: 34-39.
28. Jain AK, Venkataramanan R, Shapiro R, et al. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transpl 2002; 8: 841-5.
29. Izzedine H, Launay-Vacher V, Baumelou A, Deray G. Antiretroviral and immunosuppressive drug-drug interactions: an update. Kidney Int 2004; 66: 532-41.
30. Brinkman K, Huysmans F, Burger DM. Pharmacokinetic interaction between saquinavir and cyclosporine. Ann Intern Med 1998; 129: 914-5.
31. Jain AK, Venkataramanan R, Fridell JA, et al. Nelfinavir, a protease inhibitor, increases sirolimus levels in liver transplantation patient: a case report. Liver Transpl 2002; 8: 838-40.
32. Vogel M, Voigt E, Michaelis HC, et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transpl 2004; 10: 939-44.
33. Tseng A, Nguyen ME, Cardella C, Humar A, Conly J. Probable interaction between efavirenz and cyclosporine. AIDS 2002; 16: 505-6.
34. Margolis D, Kewn S, Coull JJ, et al. The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. J Acquir Immune Defic Syndr 2002; 31: 45-9.
35. Roland M, Stock P. Liver transplantation in HIV-infected recipients. Semin Liver Dis 2006; 26: 273-81.